A Phase 1 Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

ID Number 10-1383

Principal Investigator(s)
Ajai Chari

Department(s) or Division(s)
Hematology and Medical Oncology


ARRY-520 is an experimental drug that has not been approved by the Food and Drug Administration (FDA) or any other regulatory agency in any country. ARRY-520 interferes with a type of protein in cells called kinesin spindle protein (KSP).  KSP is necessary for most kinds of cells to multiply. Since cancer cells are multiplying much faster than normal, healthy cells, ARRY-520 may slow or stop the growth of cancer cells.


The purpose of this study is to:

  • Collect information about the safety of a drug called ARRY-520, given in two different schedules, in combination with bortezomib (also called Velcade™) with and without dexamethasone, to see what effects it has on people with Multiple Myeloma or Plasma Cell Leukemia.
  • Find the highest dose of ARRY-520, given in two different schedules, in combination with bortezomib with and without dexamethasone, which can be given to people without causing unacceptable side effects.
  • To see how ARRY-520 together with bortezomib with and without dexamethasone affects the body and peoples’ cancer.
  • In some parts of the study only: To learn how the body processes ARRY-520 and bortezomib


People may qualify to take part in this research study because their cancer, either multiple myeloma or plasma cell leukemia, has recurred after, or progressed during, treatment with standard therapy.


Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: No